21 Most Volatile Biopharma Stocks Closing Out 2012

BOSTON ( TheStreet) -- We're less than two months from putting 2012 to bed but an astonishing number of biopharmaceutical firms still have significant stock-moving catalysts that have yet to play out.

Here's an alphabetized list of 21 biotech and drug companies with FDA drug approvals and significant clinical trial results expected before the end of 2012.

Acadia Pharmaceuticals ( ACAD): Top-line results from a phase III study of pimavanserin in patients with Parkinson's disease psychosis expected in November. Read more on the BioRunUp trade in Acadia and a deeper dive into previous pimavanserin studies.

Alexza Pharmaceuticals' ( ALXA) Adasuve, an inhaled formulation of the antipsychotic medication loxapine, is expecting an FDA approval decision on Dec. 21. U.S. regulators have rejected Adasuve twice previously.

When Amarin ( AMRN) reports third-quarter results on Thursday, Nov. 8, investors will be listening for an update on Vascepa's New Chemical Entity (NCE) status and plans for the drug's commercial launch.

Amicus Therapeutics ( FOLD) and partner GlaxoSmithKline ( GSK) will announce top-line results from two phase III studies of migalastat (Amigal) in Fabry disease before the end of the year.

Biogen Idec ( BIIB) will complete a busy year of drug development when it announces results from a phase III study of dexpramipexole in amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. Data expected before end of the year.

Biomarin Pharmaceuticals ( BMRN): Phase III study of GALNS for MPS IV also known as Morquio Syndrome before end of year. If the study is successful and the drug is approved, GALNS could double Biomarin's revenue over the next five years

Catalyst Pharmaceutical Partners ( CPRX)has promised results from a phase IIb study of CPP-109 (vigabatrin) in cocaine addiction before the middle of November. That means data this week or next.

Celgene ( CELG): Top-line results from the phase III study of Abraxane in pancreatic cancer before the end of the year. TheStreet contributor Nate Sadeghi predicts a win for Celgene from this important Abraxane study.

Last May, Celldex Therapeutics ( CLDX) reported interim results from a mid-stage study of its targeted cancer drug CDX-011 demonstrating superior response rates in patients with advanced metastatic breast cancer compared to single-agent chemotherapy. Updated results from this study will be presented at the San Antonio Breast Cancer Symposium in December.

Celsion ( CLSN): Top-line results from the phase III trial of Thermodox in liver cancer expected before the end of the year. The "HEAT" study compares Thermodox plus radiofrequency thermal ablation (RFA) versus RFA alone in patients with primary liver cancer. The primary endpoint of the study is improvement in progression-free survival.

Clovis Oncology ( CLVS): Top-line results from a phase III study of CO-011 in pancreatic cancer expected before year's end. The "LEAP" study compares CO-011 versus gemcitabine in metastatic, chemo-naive pancreatic cancer patients whose tumors express low levels of hENT1, a protein which gemcitabine requires to enter cells. Survival is the study's primary endpoint.

Dynavax ( DVAX) brings its hepatitis B vaccine Heplisav in front of an FDA advisory panel on Nov. 14.

FDA will announce an approval decision for Exelixis' ( EXEL) medullary thyroid cancer drug cabozantinib on or before Nov. 29.

Gilead Sciences ( GILD) presents important new data on its all-oral hepatitis C combination regimens at the American Association for the Study of Liver Disease annual meeting beginning Saturday, Nov. 10.

An FDA advisory panel convenes Dec. 20 to review Hemispherx Biopharma's ( HEB) Ampligen as a treatment for chronic fatigue syndrome.

Nektar Therapeutics ( NKTR) will release results from a phase III studies of NKTR-118 in opioid-induced constipation before the end of the year. The "KODIAC" trials, consisting of two phase III placebo-controlled efficacy and an open-label, placebo-controlled long-term safety study, are designed to determine the efficacy and safety of NKTR-118, a once-daily tablet, for the treatment of constipation in patients taking prescription opioid medications.

NPS Pharmaceuticals ( NPSP) is expecting an FDA approval decision for Gattex on Friday, Dec. 28. Gattex treats patients with short-bowel syndrome. An FDA advisory panel voted last month to recommend the drug's approval.

Pfizer ( PFE) awaits an FDA decision on Nov. 21 for tofacitinib, the first rheumatoid arthritis pill.

Vical ( VICL): Top-line results before the end of the year for the phase III melanoma study of Allovectin (injected directly into melanoma lesions) versus dacarbazine or temozolomide in patients with recurrent metastatic melanoma. The primary endpoint of the study is durable response rate at 24 weeks but the more important and necessary (for approval) secondary endpoint is overall survival.

Vivus ( VVUS) reports third-quarter financial results on Tuesday, Nov. 6, including the first reported sales for its weight-los pill Qsymia.

Ziopharm ( ZIOP) set to announced results from the phase III study of palifosfamide in sarcoma. The "PICASSO III" study compares palifosfamide plus doxorubicin to doxorubicin alone in patients with front-line metastatic soft-tissue sarcoma. The study's primary endpoint is improvement in progression-free survival (for accelerated approval) and overall survival (for full approval.)

Sources: TheStreet research; BioMedTracker, a provider of independent research on biotechnology and pharmaceutical developments; and company and analyst reports.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz

Video: This Startup Connects Buyers and Sellers of Legal Marijuana

Video: This Startup Connects Buyers and Sellers of Legal Marijuana

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit